METiS TechBio

METiS TechBio is a biotechnology company that leverages artificial intelligence to design drugs and develop innovative therapies, particularly focusing on the longevity market. The company views aging as a process of accumulated errors in genetic code that can be reprogrammed and reversed using AI. Recently, METiS TechBio made a significant debut on the Hong Kong stock exchange, with its shares surging 173% on the first day of trading. This strong investor reception highlights the buoyant sentiment surrounding AI-related stocks and the growing interest in the multi-billion dollar longevity sector. The company's approach involves using AI to "read, rewrite and reverse cells," aiming to slow or even reverse the aging process by addressing errors in DNA sequences. Their innovative technology also includes the development of nano-rockets for drug delivery, positioning them as a key player in the future of medicine and age-related disease treatment.